Treatment Archives | VJNeurology

Trofinetide approved by FDA as first ever treatment for Rett syndrome

On March 10th 2023, the Food and Drug Administration (FDA) approved trofinetide in the treatment of Rett syndrome (RTT), making…

First ever targeted treatment for SOD1-ALS: FDA approve tofersen

On April 25th, 2023, the U.S. Food and Drug Administration (FDA) approved tofersen (BIIB067) for the treatment of amyotrophic lateral…

Relaunching the GENERATION HD trial: how will tominersen fare with younger, milder Huntington’s disease patients?

Following the termination of the GENERATION HD1 trial in March 2021, Roche have now announced plans for a new Phase…

FDA approves ublituximab for relapsing multiple sclerosis

The Food and Drug Administration (FDA) approved ublituximab for the treatment of relapsing forms of multiple sclerosis (MS), making it…

Highlights from ECTRIMS 2022

In this feature, we spotlight hot topics in MS discussed at ECTRIMS, from the inclusion of optic nerve lesions in…

MR CLEAN-LATE results presented at the World Stroke Congress 2022

The MR CLEAN-LATE prospective, randomized study of over 500 patients with acute ischemic stroke showed that endovascular thrombectomy (EVT) provides…

AMX0035 receives FDA approval for ALS

On September 29, 2022, the Food and Drug Administration (FDA) approved AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS),…

Intravenous thrombolysis in patients with ischemic stroke and DOAC intake

Current guidelines warn against the use of intravenous thrombolysis in patients with ischemic stroke and recent direct oral anticoagulant (DOAC)…

Updates on direct oral anticoagulants and hemorrhagic stroke

A wealth of research continues to investigate anticoagulation-associated intracranial hemorrhage and the optimal strategies for prevention and management…

AMT-130: the first gene therapy on the horizon for Huntington’s disease?

The first interim data has been published from a Phase I/II trial testing the safety and tolerability of AMT-130. If…

BTK inhibitors: From the treatment of cancer to multiple sclerosis

The role of BTK inhibitors (BTKis) in cancer treatment has been well-established, but what prospects do they have in treating…

New stroke guidelines: MSUs for prehospital stroke management and IVT before MT in patients with acute ischemic stroke

The European Stroke Organisation (ESO) has published new guidelines for prehospital management of suspected stroke patients, and recommendations, in collaboration…

New in epilepsy: promising therapeutic strategies

New treatment strategies are gaining attention in epilepsy, where current therapeutic options are ineffective for many. Learn more about the…

Epstein-Barr virus may be the predominant trigger of multiple sclerosis

A record-breaking study into the relationship between Epstein-Barr virus (EBV) infection and multiple sclerosis (MS) onset has revealed a 32-fold…

COVID-19 vaccination in patients with multiple sclerosis

Real-world data sets were presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS),…

Key themes in Parkinson’s disease research in 2021

Learn more about the major research themes in Parkinson’s disease, discussed at the International Congress of Parkinson’s Disease and Movement…

features: Treatment